Published in J Allergy Clin Immunol on October 01, 2008
Signaling by the phosphoinositide 3-kinase family in immune cells. Annu Rev Immunol (2013) 2.09
PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. Biochem J (2012) 1.56
p110γ/δ Double-Deficiency Induces Eosinophilia and IgE Production but Protects from OVA-Induced Airway Inflammation. PLoS One (2016) 1.40
Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation. Curr Opin Immunol (2011) 1.28
Immature B cells preferentially switch to IgE with increased direct Sμ to Sε recombination. J Exp Med (2011) 1.24
Akt and mTOR in B Cell Activation and Differentiation. Front Immunol (2012) 1.16
PI3Ks in lymphocyte signaling and development. Curr Top Microbiol Immunol (2010) 1.12
Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies. Front Immunol (2012) 1.12
mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition. Proc Natl Acad Sci U S A (2014) 0.98
The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases. Open Rheumatol J (2012) 0.97
The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions. Front Immunol (2012) 0.95
Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function. J Biol Chem (2012) 0.94
Role of SHIP-1 in the adaptive immune responses to aeroallergen in the airway. PLoS One (2010) 0.84
Imbalanced PTEN and PI3K Signaling Impairs Class Switch Recombination. J Immunol (2015) 0.83
PI3Kδ and primary immunodeficiencies. Nat Rev Immunol (2016) 0.81
Role of phosphoinositide 3-kinase in the pathogenesis of acute pancreatitis. World J Gastroenterol (2014) 0.78
PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL). Curr Top Microbiol Immunol (2016) 0.76
Lyn kinase represses mucus hypersecretion by regulating IL-13-induced endoplasmic reticulum stress in asthma. EBioMedicine (2016) 0.75
Phosphoinositide 3-Kinase in Asthma: Novel Roles and Therapeutic Approaches. Am J Respir Cell Mol Biol (2016) 0.75
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature (2010) 17.31
Requirement of bic/microRNA-155 for normal immune function. Science (2007) 16.24
A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell (2006) 10.06
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol (2009) 9.63
IRE1 signaling affects cell fate during the unfolded protein response. Science (2007) 9.01
Targets of the cyclin-dependent kinase Cdk1. Nature (2003) 8.05
Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science (2009) 7.80
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature (2007) 6.56
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell (2006) 6.15
Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science (2002) 6.01
T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A (2008) 5.97
The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature (2012) 5.61
Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science (2005) 5.53
Inhibitor hijacking of Akt activation. Nat Chem Biol (2009) 4.91
CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood (2010) 4.69
Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. Nat Immunol (2008) 4.69
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature (2013) 4.43
The site-specific installation of methyl-lysine analogs into recombinant histones. Cell (2007) 4.22
Features of selective kinase inhibitors. Chem Biol (2005) 4.07
Rewiring of genetic networks in response to DNA damage. Science (2010) 4.03
PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol (2003) 3.92
The unfolded protein response signals through high-order assembly of Ire1. Nature (2008) 3.87
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol (2008) 3.84
Evidence for lifespan extension and delayed age-related biomarkers in insulin receptor substrate 1 null mice. FASEB J (2007) 3.83
Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell (2010) 3.79
Targeting the cancer kinome through polypharmacology. Nat Rev Cancer (2010) 3.74
Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature (2006) 3.71
The Ipl1-Aurora protein kinase activates the spindle checkpoint by creating unattached kinetochores. Nat Cell Biol (2005) 3.61
Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal (2010) 3.35
A chemical-genetic strategy implicates myosin-1c in adaptation by hair cells. Cell (2002) 3.34
Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage. Science (2013) 3.33
Chemical genetic analysis of the time course of signal transduction by JNK. Mol Cell (2006) 3.32
Shaping development of autophagy inhibitors with the structure of the lipid kinase Vps34. Science (2010) 3.20
Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature (2008) 3.19
Functional organization of the S. cerevisiae phosphorylation network. Cell (2009) 3.15
The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat Chem Biol (2010) 3.15
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res (2009) 3.14
Chemical genetic screen for AMPKα2 substrates uncovers a network of proteins involved in mitosis. Mol Cell (2011) 2.99
A chemical-genetic approach to studying neurotrophin signaling. Neuron (2005) 2.93
Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A (2006) 2.91
Arterial-venous segregation by selective cell sprouting: an alternative mode of blood vessel formation. Science (2009) 2.82
The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci U S A (2008) 2.81
Control of landmark events in meiosis by the CDK Cdc28 and the meiosis-specific kinase Ime2. Genes Dev (2003) 2.79
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A (2009) 2.77
The F box protein Dsg1/Mdm30 is a transcriptional coactivator that stimulates Gal4 turnover and cotranscriptional mRNA processing. Cell (2005) 2.75
Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature (2004) 2.73
Chemical genetic analysis of Apg1 reveals a non-kinase role in the induction of autophagy. Mol Biol Cell (2003) 2.72
Evolution of phosphoregulation: comparison of phosphorylation patterns across yeast species. PLoS Biol (2009) 2.67
A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res (2007) 2.62
PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. J Exp Med (2012) 2.58
Covalent capture of kinase-specific phosphopeptides reveals Cdk1-cyclin B substrates. Proc Natl Acad Sci U S A (2008) 2.53
Cutting edge: the Foxp3 target miR-155 contributes to the development of regulatory T cells. J Immunol (2009) 2.51
A second-site suppressor strategy for chemical genetic analysis of diverse protein kinases. Nat Methods (2005) 2.47
Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol (2007) 2.43
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med (2010) 2.42
A semisynthetic epitope for kinase substrates. Nat Methods (2007) 2.40
Chemical genetics reveals the requirement for Polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cells. Proc Natl Acad Sci U S A (2007) 2.37
Phosphoproteomic analysis reveals interconnected system-wide responses to perturbations of kinases and phosphatases in yeast. Sci Signal (2010) 2.36
Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood (2005) 2.35
Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature (2012) 2.33
Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha. Cancer Cell (2008) 2.32
JNK2 is a positive regulator of the cJun transcription factor. Mol Cell (2006) 2.32
Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nat Chem Biol (2007) 2.31
Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells. J Immunol (2006) 2.29
EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell (2013) 2.28
Two cyclin-dependent kinases promote RNA polymerase II transcription and formation of the scaffold complex. Mol Cell Biol (2004) 2.26
Activation of c-Kit in dendritic cells regulates T helper cell differentiation and allergic asthma. Nat Med (2008) 2.25
Calcium-dependent protein kinase 1 is an essential regulator of exocytosis in Toxoplasma. Nature (2010) 2.25
Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. Mol Cell (2007) 2.22
An integrated platform of genomic assays reveals small-molecule bioactivities. Nat Chem Biol (2008) 2.21
PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Cancer Res (2008) 2.20
Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism. Immunity (2011) 2.17
The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development. Sci Signal (2010) 2.15
Nuclear HuR accumulation through phosphorylation by Cdk1. Genes Dev (2008) 2.14
An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol (2005) 2.11
To stabilize neutrophil polarity, PIP3 and Cdc42 augment RhoA activity at the back as well as signals at the front. J Cell Biol (2006) 2.10
Chemical genetics: where genetics and pharmacology meet. Cell (2007) 2.09
Arabidopsis MAP kinase 4 regulates salicylic acid- and jasmonic acid/ethylene-dependent responses via EDS1 and PAD4. Plant J (2006) 2.07
A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Nature (2011) 2.07
Mps1 directs the assembly of Cdc20 inhibitory complexes during interphase and mitosis to control M phase timing and spindle checkpoint signaling. J Cell Biol (2010) 2.07
Tuning the activation threshold of a kinase network by nested feedback loops. Science (2009) 2.03
Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood (2005) 2.01
Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc Natl Acad Sci U S A (2007) 1.98